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Abstract
Endogenous cannabinoid signalling is widespread throughout the body, and considerable evidence supports its
modulatory role in many fundamental physiological processes. The daily and seasonal cycles of the relationship
of the earth and sun profoundly affect the terrestrial environment. Terrestrial species have adapted to these
cycles in many ways, most well studied are circadian rhythms and hibernation. The purpose of this review was to
examine literature support for three hypotheses: (i) endocannabinoid signalling exhibits brain region‐specific
circadian rhythms; (ii) endocannabinoid signalling modulates the rhythm of circadian processes in mammals;
and (iii) changes in endocannabinoid signalling contribute to the state of hibernation. The results of two novel
studies are presented. First, we report the results of a study of healthy humans demonstrating that plasma
concentrations of the endocannabinoid, N‐arachidonylethanolamine (anandamide), exhibit a circadian rhythm.
Concentrations of anandamide are threefold higher at wakening than immediately before sleep, a relationship
that is dysregulated by sleep deprivation. Second, we investigated differences in endocannabinoids and
congeners in plasma from Marmota monax obtained in the summer and during the torpor state of hibernation.
We report that 2‐arachidonoylglycerol is below detection in M. monax plasma and that concentrations of
anandamide are not different. However, plasma concentrations of the anorexigenic lipid oleoylethanolamide
were significantly lower in hibernation, while the concentrations of palmitoylethanolamide and 2‐oleoylglycerol
were significantly greater in hibernation. We conclude that available data support a bidirectional relationship
between endocannabinoid signalling and circadian processes, and investigation of the contribution of
endocannabinoid signalling to the dramatic physiological changes that occur during hibernation is warranted.
This article is part of a themed issue on Cannabinoids. To view the editorial for this themed issue visit
http://dx.doi.org/10.1111/j.1476‐5381.2010.00831.x
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Introduction
We live in a world in which periodic environmental change, driven by geophysical cycles, dominates the activity
of life (Foster and Roenneberg, 2008). The most obvious cyclical change is the circadian/diurnal light–dark cycle,
driven by the 24 h rotational period of the earth around its axis, which influences patterns of sleep and
arousal. Because the metabolic and behavioral requirements of an organism are different between sleep and
arousal states, many other physiological processes are also circadian (Lemmer, 2009). For example, the drive to
eat is most efficiently expressed during the active period of the light–dark cycle. Similarly, metabolic rate and
core body temperature exhibit clear circadian rhythms.
Temperate and polar regions experience yearly cycles in the intensity and duration of sunlight reaching the
earth. To survive, plant and animal species that live in these regions must cope with circannual changes in the
availability of food and water, and in external temperature (Foster and Roenneberg, 2008). One remarkable
example of such adaptation is hibernation, a set of highly coordinated, physiological, biochemical and behavioral
processes that occur during the season of winter (Carey et al., 2003a).
Endogenous cannabinoid signalling (ECS) is broadly utilized throughout the body as a mechanism to regulate
intercellular communication. There is evidence that pharmacological manipulation of cannabinoid (CB) receptor
signalling affects sleep/wake cycles (Murillo‐Rodriguez, 2008b), temperature regulation (Maccarrone and
Wenger, 2005), food consumption and fat storage (de Kloet and Woods, 2009), CNS regulation of autonomic
(Pacher et al., 2005) and endocrine functions (Maccarrone and Wenger, 2005), reward‐driven behaviour
(Solinas et al., 2008), gastrointestinal function (Aviello et al., 2008), mood (Hill and Gorzalka, 2009) and
sensory perception (Biro et al., 2009). All of these processes are altered in a cyclical manner.
The goal of this review was to present the hypotheses that ECS is influenced by circadian and circannual cycles,
and that circadian and circannual cycles influence biology via changes in ECS. The interactions between ECS and
circadian cycles have been the subject of several studies, and these are reviewed herein. However, there are no
data regarding either the roles of the ECS in hibernation or the effects of hibernation on ECS; therefore, our goal
in that section was to provide food for thought and ideas for future experiments.

Essentials of ECS
ECS consists of two arachidonate ligands, N‐arachidonylethanolamine (AEA; anandamide) (Devane et al., 1992)
and 2‐arachidonoylglycerol (2‐AG) (Mechoulam et al., 1995; Sugiura et al., 1995), and at least two G‐protein‐
coupled receptors, CB receptor types 1 (CB1) (Matsuda et al., 1990) and 2 (CB2) (Munro et al., 1993). In
addition, intracellular AEA also targets the vanilloid receptor (TRPV1), which has led to the hypothesis that it
could be a second messenger that regulates calcium signalling through this receptor (De Petrocellis and Di
Marzo, 2009). Both AEA and 2‐AG are the arachidonate members of larger lipid families: the N‐
acylethanolamines (NAEs) and the 2‐monoacylglycerols (2‐MAGs). While these other family members have
overlapping synthetic and catabolic processes, with few exceptions (Hillard and Campbell, 1997), they do not act
via the CB receptors.
Available data indicate that 2‐AG is produced by post‐synaptic neurons in response to metabotropic receptor
activation and/or depolarization, and targets CB1 receptors present on pre‐synaptic terminals (Pan et al.,

2009). Thus, 2‐AG mediates activity‐dependent retrograde inhibition of synaptic activity in many brain regions
(Patel and Hillard, 2009). In all but one reported case (Azad et al., 2004), AEA is not involved in this process.
Neither the mechanisms involved in the regulation nor in the function of AEA–CB1 receptor signalling are well
understood. Interestingly, AEA is a partial agonist of the CB1 receptor (Kearn et al., 1999), and its extracellular
concentration is lower than 2‐AG (Caille et al., 2007). It is possible that AEA provides low intensity tonic
activation of CB1 receptor signalling, while 2‐AG functions as a phasic high‐intensity signal.
It is generally accepted that endogenous activation of the CB1 and CB2 receptors is regulated by processes that
govern the biosynthesis and catabolism of the endocannabinoids AEA and 2‐AG. AEA concentrations are
regulated by the conversion of a minor phosphoglyceride, N‐arachidonyl‐phosphatidylethanolamine (N‐
arachPE), via either a phospholipase D (NAPE‐PLD) (Okamoto et al., 2009) or a two‐enzyme pathway that
involves an alpha, beta hydrolase (ABH4) and a glycerophosphodiesterase (GDE1) (Simon and Cravatt, 2008).
The mechanisms that regulate the activities of these enzymes and the specifics of their involvement in the
synthesis of AEA are currently not well understood. At least three enzymes are involved in the catabolism of
AEA: fatty acid amide hydrolase (FAAH) (Cravatt et al., 1996), a lysosome‐localized fatty acyl amide hydrolase
with an acid optimum (NAAA) (Tsuboi et al., 2005) and a recently identified FAAH‐2 localized in lipid droplets
(Kaczocha et al., 2009).
2‐AG is synthesized via a two‐enzyme cascade of phospholipase C (PLC) and diacylglycerol lipase (DGL). Recent
evidence suggests that in neurons, the rate‐limiting step for the synthesis of CB1 receptor‐targeted 2‐AG is DGL
(Bisogno et al., 2003; Yoshida et al., 2006; Gao et al., 2010). 2‐AG is hydrolysed by several enzymes; in
brain, 85% of the hydrolysis occurs via monoacylglycerol lipase (MGL), the remaining is hydrolysed by ABHD6
and ABHD12 (Blankman et al., 2007), enzymes about which far less are known. AEA and 2‐AG are also
substrates for some arachidonate oxygenases, including lipoxygenases (Edgemond et al., 1998) and COX 2
(Kozak et al., 2002).
Several generalities about ECS are supported by considerable experimental evidence. First, ECS is widespread. In
addition to very prominent expression within the brain, ECS has been identified in the spinal cord (Hohmann,
2002), sympathetic nervous system (Ralevic and Kendall, 2009), enteric nervous system (Massa and Monory,
2006), liver (Mallat and Lotersztajn, 2008), adipose tissue (Nogueiras et al., 2009), immune system (Munro et
al., 1993) and pancreas (Juan‐Pico et al., 2006).
Second, ECS is modulatory. Within the CNS, the CB1 receptor is located on pre‐synaptic terminals, and functions
to inhibit neurotransmitter release (Patel and Hillard, 2009). CB1 receptors also regulate transmitter release
from sympathetic terminals (Pakdeechote et al., 2007), enteric nerves (Tyler et al., 2000; Massa and Monory,
2006) and peripheral sensory nerves (Agarwal et al., 2007).
Third, ECS is plastic; in fact, multiple mechanisms have been identified for the regulation of ECS. As was outlined
above, enzymatic mechanisms regulate the biosynthesis and catabolism of the endocannabinoids. In addition,
conditions have been identified that regulate CB receptor expression. For example, hippocampal CB1 receptors
are down‐regulated by chronic stress (Hill et al., 2005) and macrophage CB2 receptor expression changes with
alterations in cellular activation (Carlisle et al., 2002). At the systems level, the plasticity of ECS allows for
context‐dependent signalling.
Fourth, ECS serves a homeostatic role. At the synaptic level, this is seen in its function as an activity‐dependent
retrograde mediator of synaptic transmission (Freund et al., 2003). At glutamatergic synapses,
endocannabinoids are mobilized in response to glutamate activation of metabotropic receptors and/or
depolarization, and serve to reduce excitatory drive. At a systems level, activation of the ECS contributes to
recovery from activation of the hypothalamic–pituitary–adrenal (HPA) axis, for example (Di et al., 2003).

ECS and the circadian cycle
ECS is intertwined with the circadian rhythm in several respects. Amounts of the endocannabinoids, their
degradative and synthetic enzymes and their receptors all show tissue‐specific diurnal changes, indicating that
ECS is ‘downstream’ of circadian regulators. On the other hand, exogenous and endogenous CBs affect many
important physiological processes that exhibit a circadian rhythm: sleep–wakefulness, body temperature, HPA
endocrine secretions, food intake, learning and memory and locomotor activity. These findings indicate that ECS
is ‘upstream’ of circadian processes. Therefore, a central thesis of this review is that ECS serves as a link between
circadian regulators, such as the intrinsic clock of the suprachiasmatic nucleus (SCN) and the physiological
processes that they affect.

The circadian rhythm of ECS components

There is evidence that ECS exhibits a circadian rhythm with variations reported in endocannabinoid tissue
contents (Valenti et al., 2004; Murillo‐Rodriguez et al., 2006), CB1 receptor number (Martinez‐Vargas et al.,
2003; Rueda‐Orozco et al., 2008) and in the enzymes controlling the synthesis and degradation of
endocannabinoids (Valenti et al., 2004).
Because endocannabinoids are mobilized ‘on‐demand’, their concentrations in lipid extracts of isolated brain
regions are hypothesized to be proportional to their concentrations in the synapse. In Sprague‐Dawley rats,
significant diurnal variations in AEA and 2‐AG contents have been demonstrated in CSF, hypothalamus,
hippocampus, pons, nucleus accumbens, prefrontal cortex and striatum (Valenti et al., 2004; Murillo‐Rodriguez
et al., 2006). With respect to AEA concentrations, two patterns have been reported. In the pons (Valenti et
al., 2004; Murillo‐Rodriguez et al., 2006), nucleus accumbens, prefrontal cortex, hippocampus and striatum
(Valenti et al., 2004), AEA content is higher in tissues harvested during the active phase of the rats (i.e. when
the lights are off) than during the inactive phase. An opposite pattern is seen in CSF and hypothalamus, where
AEA concentrations are higher in the inactive than in the active phase (Murillo‐Rodriguez et al., 2006). These
studies suggest that AEA‐mediated signalling varies with time of day and that multiple mechanisms link the
circadian rhythms with changes in AEA biosynthesis and/or clearance. In a few cases, the mechanism could
involve changes in the activity of FAAH. One study found that FAAH activity was negatively correlated with AEA
content in the hippocampus and striatum, suggesting that circadian changes in FAAH activity could underlie the
changes in AEA content in those regions (Valenti et al., 2004). However, a recent study comparing FAAH
activity at the midpoint of the light and dark phases did not find differences in either striatum or hippocampus,
but did report small but significant differences in FAAH activity in the cerebellum and periaqueductal gray at
these time‐points (Glaser and Kaczocha, 2009).
Interestingly, the tissue contents of 2‐AG were opposite to those of AEA in tissues where both were measured.
2‐AG contents were higher during the inactive phase (day) in nucleus accumbens, prefrontal cortex, striatum
and hippocampus (Valenti et al., 2004). In the striatum, the activities of both MGL and DGL are higher during
the inactive than active phase (Valenti et al., 2004); increased DGL activity in particular is consistent with
higher turn‐over of 2‐AG during the inactive phase in the striatum. On the other hand, no changes in MGL or
DGL were seen in the hippocampus (Valenti et al., 2004), suggesting divergent mechanisms for the regulation
of 2‐AG between striatum and hippocampus.
There is evidence that CB1 receptor density in rat brain is regulated in a circadian manner. In both pons
(Martinez‐Vargas et al., 2003) and hippocampus (Rueda‐Orozco et al., 2008), the density of CB1 receptor
protein is approximately 5% higher during the inactive than the active phase. The pattern of protein expression
is similar in both regions, with peaks at the midpoint in the light period and troughs 12 h later. CB1 receptor
mRNA expression exhibits a more substantial diurnal variation, with increases of 11% in the pons (Martinez‐
Vargas et al., 2003) and 50% in the hippocampus (Rueda‐Orozco et al., 2008). In both regions, mRNA
concentrations are out of phase with the changes of CB1 receptor protein over a 24 h period, but the patterns

are slightly different. Neither protein nor mRNA for CB1 receptors varies significantly in the striatum (Rueda‐
Orozco et al., 2008).
The changes in endocannabinoid content and CB1 receptor density with time of day in the pons and
hippocampus display interesting relationships. In both brain regions, AEA content and CB1 receptor protein
concentration are nearly perfectly out of phase with each other (Figure 1A,B). For the majority of the inactive
phase, CB1 receptor density is high and AEA content is low in the hippocampus. We hypothesize that CB1
receptor signalling is in a state of low basal tone (due to low AEA concentrations) and high sensitivity to 2‐AG
activation (Figure 1C). The finding that hippocampal 2‐AG content is higher in the inactive phase suggests that
its synthesis is greater or clearance is reduced during this phase, which could also contribute to a situation in
which CB1 receptor activation by 2‐AG is potentiated. When the animals are awake and active, AEA tone is high,
while CB1 receptor density is slightly lower. We hypothesize that this results in higher basal tone, but reduced
efficacy of 2‐AG activation (Figure 1C). We propose a similar mechanism is operative in the pons; however, the
period of time during which AEA content is high, and thus CB1 receptor signalling is less sensitive to 2‐AG, is
confined to the first half of the active phase. Previous studies demonstrating that CB1 receptor agonists increase
neuronal activity in the locus coeruleus (Muntoni et al., 2006) and that neuronal activity in the locus coeruleus
neurons is greater in the active period than the inactive period (Aston‐Jones et al., 2001) suggest the intriguing
hypothesis that high AEA concentrations in the active phase contribute to the awake state supported by high
locus coeruleus output. Interestingly, AEA content in the hypothalamus exhibits the opposite relationship to
time which, if the hypothesis presented above is correct, would result in high basal CB1 receptor signalling
during the inactive phase.

Figure 1
Schematic of the relationship between time and changes in AEA content and CB1 receptor protein expression in
hippocampus (A) and pons (B). The data plotted were taken from Martinez‐Vargas et al. (2003), Valenti et al.
(2004), Murillo‐Rodriguez et al. (2006) and Rueda‐Orozco et al. (2008); changes are displayed relative to the
high and low values reported. (C) Hypothesis of the dual regulation of the effectiveness of 2‐AG to activate CB1
receptor‐mediated signalling by AEA concentrations and the CB1 receptor density. In both of these brain regions,
AEA content is low in the inactive phase of the day, while CB1 receptor protein is at its highest concentration.
We hypothesize that this allows for high efficacy of 2‐AG activation of CB1 receptor signalling. In the active phase
of the day, CB1 receptor protein is lower, while AEA content is high; we hypothesize that this results in higher
basal receptor tone and lower maximal efficacy for 2‐AG than in the inactive phase.

Time of day and sleep deprivation affect plasma endocannabinoids in
humans

The endocannabinoids are also present in the circulation, although their source and targets are not well
understood. In a small pilot study, we explored the circadian rhythms of circulating endocannabinoids in
humans. Plasma was obtained in the late evening, early morning and early evening from five healthy humans
who had consistent sleep/wake cycles for at least 5 days prior to sampling. Lipid extracts from plasma were
obtained and concentrations of AEA and 2‐AG were determined using liquid chromatography–mass
spectrometry (LC–MS) as outlined in Hill et al. (2008). Blood samples were obtained during a 24 h stay at the
clinical research centre at the University of Chicago; the subjects remained in bed with lights out from 2230 at
day 1 until 0700 at day 2. AEA and 2‐AG contents were determined in plasma obtained at 2200 at day 1, and at
0730 and 1730 at day 2 (Figure 2A). No significant relationship between 2‐AG concentrations and time of day
was found; however, there was a highly significant effect of time on AEA concentration (F2,14= 114; P < 0.0001).
Tukey's multiple comparison test revealed a significant difference between the concentration in blood obtained
at 2200 at day 1 and at 0730 at day 2 (q= 20; P < 0.001), and between blood obtained at 0730 and 1730 at day 2
(q= 15; P < 0.001). The difference in AEA concentrations between blood obtained at 2200 at day 1 and at 1730 at
day 2 was not significant (q= 3.5; P > 0.05). These data suggest that circulating AEA concentrations rise during
sleep, although the exact pattern of change remains to be determined.

Figure 2
Blood was obtained from five (three male) subjects during two 24 h sessions in the clinical research centre of
the University of Chicago. The two sessions were 1 week apart. During one of the sessions, the subjects were in
bed with the lights out from 2230 (day 1) until 0700 (day 2) (A; normal sleep session); during the other session,
the subjects did not sleep at all (B; sleep deprivation session). The two sessions were randomized with respect to
deprivation. A study staff monitored the subjects during both visits to ensure compliance with the sleep or
deprivation conditions. Plasma was obtained in Chicago, frozen within 2 h of collection and shipped to
Milwaukee for analysis on dry ice. Endocannabinoids were extracted and measured as reported previously (Hill
et al., 2008). Lines connect data points obtained from the same subject. This study was approved by the
Institutional Review Boards of the University of Chicago and the Medical College of Wisconsin. Please see text
for the statistical comparisons.
In a second phase of the pilot study, we explored the effects of sleep deprivation on plasma endocannabinoids.
The same five individuals spent a second night in the clinical research centre during which they were not
allowed to sleep. The session (first or second) at which sleep deprivation was imposed was randomized. Plasma
endocannabinoids were determined in blood drawn at 2200 at day 1 and at both 0730 and 1730 at day 2 (Figure
2B). As evidence of the stability of circulating AEA concentrations, there was no difference in AEA concentrations
in blood drawn at 2200 between the two clinic visits, which were 1 week apart (paired t= 1.46; P= 0.22). One‐
way anova of the AEA concentrations by time of blood draw in the sleep deprivation arm also indicated a
significant effect of time (F2,14= 8.9, P < 0.01); however, the only comparison that reached significance in the
Tukey's post hoc tests was between 2200 at day 1 and 1730 at day 2 (q= 5.8; P < 0.01), a comparison that was

not significant in the same subjects allowed to sleep normally. The q value for the comparison between 2200 at
day 1 and 0730 at day 2 was 3.9, and between 0730 and 1730 at day 2 was 1.9; both P > 0.05. Therefore, these
data indicate that lack of normal sleep produces a significant dysregulation of circulating AEA. Intriguing as these
data are, it is difficult to interpret their functional significance because we know little about the regulation of
AEA concentrations in the circulation and the target of this mediator. These data are at odds with a previous
report that sleep deprivation did not significantly alter plasma AEA concentrations in blood drawn between 1000
and 1200 the day following sleep deprivation (Koethe et al., 2009). However, close inspection of data reported
in that paper indicates that sleep deprivation increased the variance in plasma AEA concentrations in accord
with the present results.

ECS and circadian rhythms
The primary circadian clock in mammals is located in the SCN, a distinct group of cells located in the
hypothalamus. Destruction of the SCN results in the complete absence of a regular sleep/wake rhythm (Weaver,
1998). The clock can be entrained or tuned by environmental factors, called zeitgebers (Roenneberg and
Merrow, 2007). The most well‐studied zeitgeber is light; other zeitgebers are environmental temperature,
availability of food and social interactions (Roenneberg and Merrow, 2007). The SCN receives information about
environmental illumination through photoresponsive retinal ganglion cells. These cells project to the SCN via the
retinohypothalamic tract (RHT) (Okamura, 2003). Other important inputs to the SCN are afferents from the
intergeniculate leaflet (IGL) of the thalamus, which integrates photic and non‐photic information (Hastings et
al., 1997), and the serotonergic projections of the raphe nuclei, which entrain the clock in a non‐photic manner
and affect light input as well (Challet, 2007).
The widespread distribution of the CB1 receptor in the brain offers support for multiple possibilities by which
ligands of this receptor could alter the response of the SCN to light input and could modulate clock outputs
(Figure 3). CB1 receptors are present in the hamster (Sanford et al., 2008) and mouse SCN (Wittmann et al.,
2007). Therefore, CB agonists could directly influence glutamate and/or GABA neurotransmission within the
SCN. In support of this possibility, Sanford et al. (2008) have recently reported that CB1 receptor activation
inhibits the phase advance in activity patterns produced by a light pulse administered to hamsters held in total
darkness. CB1 receptor antagonists had no effect alone on the light‐induced phase advance, but completely
blocked the agonist effect. Because CB1 receptors are present in the hamster SCN, these data are consistent with
a role for CBs to inhibit input to the SCN from the RHT. However, these data could also reflect CB1 receptor
inhibition of SCN outputs (Figure 3).

Figure 3
Possible mechanisms by which endocannabinoid/CB1 receptor signalling can alter inputs to the SCN and
projections from the SCN. See the text for details and references.

CB1 receptors are found in the dorsal and median raphe nuclei of the hamster (Sanford et al., 2008), and in the
raphe nuclei of rats and mice (Moldrich and Wenger, 2000; Haring et al., 2007). Serotonergic agents are
capable of inhibiting light‐induced phase shifts in a manner similar to the effect of CB1 receptor agonists
discussed above (Weber et al., 1998; Gannon and Millan, 2006). There is evidence that the raphe–
hypothalamic projection is affected by ECS. Treatment of rats with the CB1 receptor agonist CP55940 increases
hypothalamic levels of serotonin (5HT) (Arevalo et al., 2001). Pharmacological inhibition of FAAH increases
brain AEA concentrations and the firing rate of serotonergic dorsal raphe neurons via CB1 receptor activation
(Gobbi et al., 2005). The ECS could interact with the serotonergic system in the dorsal raphe nucleus (DRN) in
part through mediating the orexin modulation of glutamatergic synaptic transmission to DRN 5HT neurons (Haj‐
Dahmane and Shen, 2005). The orexins are neuropeptides involved in sleep–wakefulness, feeding and reward
(Matsuki and Sakurai, 2008; Shioda et al., 2008; Mieda and Sakurai, 2009). Orexin B acts on DRN serotonergic
neurons to stimulate the synthesis and release of 2‐AG (Haj‐Dahmane and Shen, 2005). In addition, the CB1 and
orexin receptors can form dimers that influence the localization and signalling of both receptors (Ellis et al.,
2006).
Neuropeptide Y (NPY) is released in the SCN from projections originating in the IGL (Harrington et al., 1985;
Harrington, 1997), and is thought to convey non‐photic cues to the SCN and inhibit light‐induced adjustments of
the circadian rhythm (Biello, 1995; Maywood et al., 2002). Like the CB1 receptor agonist, NPY agonists inhibit
light‐induced phase shifts (Huhman and Albers, 1994; Weber and Rea, 1997; Yannielli and Harrington, 2000;
2001). CB1 receptor agonists increase while antagonists decrease resting and evoked NPY release in rat
hypothalamic explants (Gamber et al., 2005). This mechanism is consistent with the effect of CB1 receptor
agonists to inhibit the light‐induced phase shift. The presence of CB1 immunoreactivity in the hamster IGL
(Sanford et al., 2008) supports the possibility that CB1 agonists inhibit light‐induced phase shifts through
increasing IGL–SCN afferent activity.
ECS components are present in the pineal (Koch et al., 2008), a brain region that receives multi‐synaptic relays
originating in the SCN, and synthesizes and releases melatonin. Within the pineal gland, CB1 receptors are
present in both pinealocytes and on the terminals of sympathetic afferents to the gland. Both FAAH and NAPE‐
PLD are also expressed in pinealocytes. Interestingly, NAPE‐PLD is also present in sympathetic terminals, which
leads to the possibility that an NAE could be synthesized and released as a co‐transmitter with norepinephrine.
The function of ECS within the pineal has not been studied; however, Δ9‐tetrahydrocannabinol (THC) and other
plant‐derived CBs reduce melatonin synthesis in the pineal via a non‐CB1 receptor‐dependent mechanism (Koch
et al., 2006).

ECS and sleep patterns

There is considerable evidence that ECS affects the organization of sleep. Acute administration of THC causes a
decrease in rapid eye movement sleep (REMS) in rabbits (Fujimori and Himwich, 1973), cats (Wallach and
Gershon, 1973) and humans (Pivik et al., 1972; Freemon et al., 1974), and increases slow wave sleep (SWS) in
rabbits (Fujimori and Himwich, 1973), humans (Pivik et al., 1972) and rats (Moreton and Davis, 1973).
However, chronic administration has been found to decrease SWS with inconsistent effects on REMS in humans,
cats and squirrel monkeys (Barratt and Adams, 1973; Pranikoff et al., 1973; Barratt et al., 1974; Adams and
Barratt, 1975). These findings suggest that tolerance or some other form of adaptation occurs when THC is
administered chronically.
More recent studies have explored the involvement of ECS in the control of the sleep/wake cycle. Available data
indicate that ECS maintains and/or promotes the sleep state (Murillo‐Rodriguez, 2008a). In particular, treatment
of rats with a CB1 receptor antagonist 4 h after lights on increases the time spent in wakefulness and decreases
time spent in both SWS and REMS during the subsequent 4 h (Santucci et al., 1996). Conversely, injection of
AEA i.c.v. or into the pedunculopontine tegmental nucleus at onset of light caused a decrease in wakefulness
and an increase in SWS and REMS (Murillo‐Rodriguez et al., 1998). The effect of AEA was blocked by both

rimonabant and a PLC inhibitor (Murillo‐Rodriguez et al., 2001). Inhibition of AEA clearance with AM404 also
decreased wakefulness and increased sleep, although these effects were only partially sensitive to rimonabant
(Murillo‐Rodriguez et al., 2008). Further evidence in support of a role for the ECS in the regulation of sleep
comes from studies demonstrating that CB1 receptor density is significantly increased in the rat pons during the
rebound phase following sleep deprivation (Martinez‐Vargas et al., 2003). These data suggest that increased
ECS, at the level of the receptor, could be involved in the homeostatic recovery of sleep following deprivation.

CBs and the circadian rhythm of temperature
There is considerable evidence that exogenously administered CB1 receptor agonists affect body temperature
regulation. At ‘normal’ ambient temperatures, THC produces a very significant hypothermia (in the range of 5°C
reduction in rectal temperature) (Martin et al., 1991) that is completely abolished by co‐administration of a
CB1 receptor antagonist (Hillard et al., 1999). However, studies in which ambient temperature is a variable
indicate that mice become poikilothermic when treated with THC (Bloom and Kiernan, 1980). More recently,
investigators have utilized intra‐hypothalamic injection of direct and indirect agonists of the CB1 receptor to
study the effects of ECS on thermoregulation. The available results are contradictory, demonstrating that
agonists both increase (Fraga et al., 2009) and decrease core body temperature (Benamar et al., 2009) in a
CB1 receptor‐dependent manner.
Most mammals exhibit a daily circadian rhythm in body temperature, which is higher during the active phase
than the inactive phase (Kelly, 2006). This rhythm is regulated by cyclical release of melatonin by the pineal
gland; a higher melatonin release during the inactive phase correlates with and likely drives lower body
temperature (Cagnacci et al., 1997). The hypothermic effect of THC is greatest in the second half of the
inactive phase, less in the first half of the inactive phase and least in the active phase (Abel, 1973). This suggests
that THC could function to potentiate the secretion of melatonin. Interestingly, there is some functional
evidence that THC inhibits noradrenergic increases in melatonin synthesis, perhaps via inhibition of
norepinephrine release from sympathetic terminals in the pineal (Koch et al., 2006; 2008), a result opposite of
the outlined expectation.
Brain temperature also exhibits a circadian rhythm (Aschoff et al., 1973). Exogenous administration of CBs
disrupts the circadian rhythm of brain temperature. Daily injection of rats with THC for 1 week caused the
circadian variation in brain temperature to be diminished (Perron et al., 2001). Further, there was a gradual
lengthening of cycle duration such that by the end of the treatment period, the brain temperature rhythm of
THC‐injected animals was 12 h out of phase relative to vehicle‐injected controls. The out‐of‐phase cycling
continued without change during a recovery week. In contrast to the marked effect on brain temperature, the
circadian rhythm of abdominal temperature was not significantly affected by THC. The finding that the presence
of exogenous CB1 receptor agonist administered at a consistent time of day entrains brain temperature suggests
that ECS is an important regulator of this process. Whether the ECS is involved in entrainment of the rhythms of
other physiological processes is not known, but is an important question.

ECS and circadian regulation of the HPA axis
There is a pronounced circadian rhythm to the secretions of corticotropin‐releasing hormone, corticotropin
(ACTH) and glucocorticoids that is controlled by the SCN (Moore and Eichler, 1972). There is also considerable
evidence that ECS regulates the activation of the HPA axis by stress (Patel et al., 2004), and is required for
normal glucocorticoid‐mediated feedback on the HPA axis (Di et al., 2003; Cota et al., 2007). Studies using
CB1 receptor null mice indicate that the fundamental rhythm of circulating glucocorticoids is intact in the global
absence of ECS (Cota et al., 2007). However, relative to wild‐type mice, CB1 receptor null mice exhibit
significantly higher circulating glucocorticoid concentrations at the onset of the active phase (Cota et al.,
2007). These data are consistent with a role for the ECS to negatively regulate HPA axis activation, likely as a
downstream mediator of glucocorticoid receptor activation (Di et al., 2003).

Hibernation is an extreme example of seasonal rhythm
Hibernation includes regulated decreases in body temperature (Tb), heart rate, respiration and metabolic rate
(Zucker, 2001; Carey et al., 2003b; Geiser, 2004). However, hibernation is not just a winter phenomenon as it
also requires ‘preparation’ for the winter food shortages through excess caloric intake during the summer
months. Thus, hibernating species exhibit dramatic shifts in feeding behaviour and fat storage, resulting in
significant changes in body weight through the year (Boswell et al., 1994; Dark, 2005). Moreover, hibernators
do not exhibit a continual state of torpor, but rather hibernation consists of cycles of torpor (minimal Tb) and
arousal (euthermia). These minimal and maximal states of body temperature are separated by distinct transition
periods called entry into torpor and arousal, respectively (see figure 4 in Carey et al., 2003a).

Figure 4
Possible mechanisms by which endocannabinoid signalling (ECS) could contribute to the feeding and metabolic
changes that occur during the late‐summer hyperphagic period and during the period of hibernation. See the
text for details and references.
The duration of day‐time sunlight (photoperiod) synchronizes the circannual rhythms of hibernation, but torpor
induction requires both a short photoperiod and low environmental temperature (Heldmaier et al., 1989). This
combined need could relate to the animal's thermogenic capacity, as short photoperiod and cold together
maximally increase brown adipose tissue mass, expression of mitochondrial uncoupling protein and lipolytic
enzymes and sympathetic innervation (Cannon and Nedergaard, 1985).
The body mass cycle is regulated by a circannual clock (Lee and Zucker, 1991; Zucker, 2001). Like circadian
rhythms, the seasonal rhythm will ‘free run’ with a period of 100 days in the absence of natural changes in the
duration of sunlight and temperature. Return to natural conditions resets the period to nearly a year, suggesting
that, like the circadian clock, the circannual clock is entrained by environmental light and temperature.

Circannual cycle and feeding behaviour
The circannual hibernation cycle is characterized by shifts from normal feeding to hyperphagia to hypophagia. A
key mediator of the circannual cycle of feeding behaviour is the anorexigenic hormone, leptin (Scarpace and
Zhang, 2009). In black bears, circulating leptin increases in late summer, remains high during hibernation and
decreases in spring (Donahue et al., 2006). Increased concentrations of leptin during hibernation are
consistent with the profound hypophagia that occurs during hibernation, and decreased concentrations of leptin
in spring likely allow for spring feeding. Leptin infusion in arctic ground squirrels following emergence from
hibernation prevents hyperphagia (Boyer et al., 1997). The occurrence of hyperphagia in late summer despite
high leptin concentrations in black bears (Donahue et al., 2006) could reflect resistance to the effects of leptin.

Consistent with this hypothesis, brown bats become leptin resistant during the period of maximal fat deposition
(Kronfeld‐Schor et al., 2000).

ECS and feeding behaviour

ECS regulates orexigenic drive in reward‐related brain regions and in the primary orexigenic nuclei of the
hypothalamus. Recent evidence demonstrates that food consumption is characterized by learned habits and can
be motivated by reinforcers (Volkow and Wise, 2005). There is clear evidence that ECS modulates the rewarding
properties of food (Kirkham et al., 2002). CB1 receptors are present in several primary relay nuclei of the
reward pathway, including the prefrontal cortex (Eggan and Lewis, 2006) and the nucleus accumbens (Lupica
and Riegel, 2005). Injection of 2‐AG into the shell of the nucleus accumbens results in increased food intake
(Kirkham et al., 2002).
The drive to eat is also regulated by the hypothalamus, and ECS occurs at multiple sites within the hypothalamic
circuits involved in metabolic regulation (Cota et al., 2006). 2‐AG levels in the hypothalamus are increased
during fasting, and decreased as the animals are re‐fed (Hanus et al., 2003), indicating that ECS in this region is
recruited by changes in feeding status. Furthermore, injection of AEA into the ventromedial hypothalamus of
satiated rats results in CB1 receptor‐mediated hyperphagia (Jamshidi and Taylor, 2001), suggesting that
increased ECS over‐rides normal satiety signals to induce inappropriate food consumption. In the context of the
cycle of hibernation, this mechanism could be beneficial during the late‐summer hyperphagic period (Figure 4).
A milestone in our understanding of the role of ECS in the regulation of satiety came from studies of Di Marzo
and Kunos demonstrating that ECS is an important effector of leptin in the hypothalamus. In particular, leptin
reduces hypothalamic contents of AEA and 2‐AG in normal mice, and mice deficient in leptin signalling are obese
and hyperphagic, and have elevated hypothalamic endocannabinoid contents (Di Marzo et al., 2001). Blockade
of the CB1 receptor in these mice results in decreased food intake, indicating that at least part of the
anorexigenic effect of leptin is due to decreased ECS. Recent evidence also suggests that increased CB1 receptor
activity is involved in the orexigenic effects of NPY (Gamber et al., 2005) and ghrelin (Tucci et al., 2004).
There is evidence that loss of leptin‐induced inhibition of ECS could contribute to some forms of leptin
resistance (Osei‐Hyiaman et al., 2008), an observation that is interesting in light of the hypothesis presented
above that late‐summer hyperphagia in bears could be an example of leptin resistance. Overall, the tight
relationship between leptin and ECS in the hypothalamus, together with the data discussed above that leptin is a
critical mediator of the transitions between late summer and hibernation, and between hibernation and spring
feeding, suggests the hypothesis that ECS is involved in the regulation of feeding in animals with a circannual
cycle.

Circannual cycles of lipid and carbohydrate metabolism
Increased body mass in hibernators is largely due to increased lipid storage in white adipose tissues (WATs), and
it is hypothesized that this process has a set point that varies circannually (Davis, 1976; Mrosovsky and Faust,
1985; Dark, 2005). Consistent with this hypothesis, limiting the foraging time of ground squirrels leads to
decreased lean body mass, but WAT fat stores are conserved (Bachman, 1994).
Hibernators also exhibit dramatic shifts in cellular sources of metabolic fuel. During active periods, both
carbohydrates and lipids are used (Buck and Barnes, 2000; Squire et al., 2003). Conversely, during torpor,
metabolic needs are met exclusively by oxidation of fatty acids (FAs). Key molecular switches in cellular
metabolism include the kinase Akt (Miyamoto et al., 2009). Activation of Akt by insulin receptor signalling
increases utilization of carbohydrates as cellular energy sources. Consistent with a shift to lipolysis during
hibernation, torpor is associated with significant decreases in Akt activity (Cai et al., 2004; Abnous et al.,
2008). Recent data in human skeletal muscle suggest that CB1 receptor activation, perhaps in response to AEA
released from adipocytes, negatively regulates insulin stimulation of Akt activation (Eckardt et al., 2009). These

data lead to the notion that adipose‐derived endocannabinoids could modulate the switch between
carbohydrate and lipid utilization during torpor (Figure 4).
Another key determinant of the cellular energy source is pyruvate dehydrogenase kinase 4 (PDK4) (Roche and
Hiromasa, 2007). PDK4 inactivates pyruvate dehydrogenase, which leads to decreased glycolysis and increased
FA oxidation. PDK4 expression is increased during hibernation (Andrews et al., 1998; Buck et al., 2002), and
likely contributes to decreased pyruvate dehydrogenase activity observed in heart and kidney of hibernating
animals (Brooks and Storey, 1992). Interestingly, PDK4 expression appears to be tonically maintained by CB1
receptor activation in skeletal muscle cells from both lean and obese humans (Cavuoto et al., 2007).

ECS and lipid storage
There is clear evidence that ECS signalling occurs in adipose tissue and functions to regulate energy homeostasis.
In particular, CB1 receptor blockade results in enhanced lipolysis in WAT through stimulation of enzymes
involved in beta‐oxidation and the tricarboxylic acid cycle; increases energy expenditure in adipose tissue via
futile cycle induction; and up‐regulates expression of glucose transporter type 4, resulting in improved glucose
utilization (Jbilo et al., 2005). Furthermore, CB1 receptor blockade results in a restoration of ‘lean’ adipocyte
morphology in cells taken from obese animals. Adipocytes also function as endocrine cells, releasing the
adipokines adiponectin and visfatin. Adiponectin is an insulin‐sensitizing hormone with anti‐inflammatory
properties (Kadowaki and Yamauchi, 2005). Visfatin is a recently discovered adipokine capable of activating the
insulin receptor and thought to promote obesity (Marra and Bertolani, 2009). CB1 receptor activation in WAT
inhibits the secretion of adiponectin and increases the secretion of visfatin, an effect that will favour insulin
resistance and weight gain (Perwitz et al., 2006). Taken together, these data suggest that high ECS in WAT is
associated with lipid storage, and more significantly, could be required for lipid storage to occur. In the context
of hibernation, these findings suggest the hypothesis that adipocyte ECS would be high during the late summer
and very low during the hibernation phase (Figure 4).
ECS in the liver is also emerging as an important player in metabolic regulation. Hepatic FA synthesis requires
intact ECS as a CB1 receptor antagonist inhibited both basal hepatic FA synthesis, as well as high‐fat diet‐induced
hepatic steatosis (Osei‐Hyiaman et al., 2005). Activation of the CB1 receptor in hepatocytes results in increased
expression of several genes involved in de novo synthesis of FAs, including the lipogenic transcription factor,
SREBP‐1c (Osei‐Hyiaman et al., 2005). Hepatocyte CB1 receptor activation also results in inhibition of AMP
kinase (Kola et al., 2005). Recent studies utilizing mice with cell‐specific deletions of the CB1 receptor in
hepatocytes strongly suggest that many of the effects of ECS on metabolism are mediated by the liver (Osei‐
Hyiaman et al., 2008). In particular, these mice became obese when fed a high‐fat diet, but did not develop
hepatic steatosis, insulin resistance or leptin resistance to the degree of wild‐type controls. As in the WAT, high
ECS tone in the liver is consistent with the pre‐hibernation phase in which metabolic fuel is preserved and stored
for later use (Figure 4).

Changes in cellular lipid composition during hibernation
WAT and cellular phospholipids from hibernating animals are relatively rich in polyunsaturated FAs (PUFAs), and
the increased lipid fluidity that results is thought to benefit the animal at lower Tb. Evidence suggests that the FA
composition of lipids in hibernating animals has a profound effect on torpor bouts, with significantly longer
bouts in animals on PUFA‐rich diets (Florant et al., 1993; Geiser et al., 1994; Dark, 2005). Hibernating animals
also appear to have regulatory mechanisms to retain PUFAs (Cochet et al., 1999). These regulatory
mechanisms include preferential oxidation of saturated FA and scavenging of MAGs that contain PUFA. Central
to the latter process is the enzyme monoacylglycerol acetyltransferase (MGAT). MGAT is highly expressed during
hibernation (Mostafa et al., 1993; Xia et al., 1993). By preferentially acylating monoacylglycerols that contain
PUFAs, MGAT facilitates their continued storage in triacylglycerides (TAGs). Ground squirrels also exhibit
significantly lower activity of cytosolic phospholipase A2 activity during hibernation (Woods and Storey, 2007), a

change that would both reduce the generation of oxidation products of arachidonic acid and preserve
phospholipid arachidonate.
The endocannabinoids are arachidonate derivatives that target the CB receptors. In addition, several studies
suggest that they could function as arachidonate donors, in particular under conditions in which arachidonic acid
is shuttled from cell to cell (Pratt et al., 1998; Gauthier et al., 2005). Therefore, the concept that PUFAs such
as arachidonic acid are handled differently during hibernation could have interesting implications for ECS.
Among many other possibilities, perhaps a reduction in the availability of arachidonic acid for signalling
purposes results in reduced ECS, which in turn contributes to the switch from fat storage to fat mobilization
during hibernation.

Changes in circulating concentrations of N‐acylethanolamines during
hibernation

Despite the intriguing overlaps between ECS function and hibernation, to our knowledge, there are no published
reports on the role or regulation of the ECS in hibernators. As a first step in addressing this question, plasma
lipids from summer‐active (SA) and torpid (T) Marmota monax (common names are groundhog and woodchuck)
were analysed using LC–MS for the two endocannabinoids and several related lipids (Figure 5). Interestingly,
concentrations of 2‐AG could not be detected in plasma from any of the M. monax. This is remarkable in light of
the nM concentrations of 2‐AG measured in plasma and/or serum from humans (Hill et al., 2008; 2009). In
contrast, AEA was detectable in M. monax plasma at concentrations of 2–7 nM, which is approximately
threefold greater than its concentration in human serum. The concentration of AEA was not different in plasma
from M. monax in the SA (3.67 ± 0.98 pmol·mL−1) and T (4.00 ± 0.98 pmol·mL−1). In contrast, plasma
concentrations of palmitoylethanolamide (PEA) and 2‐oleoylglycerol (2‐OG) increased during torpor, whereas
concentrations of oleoylethanolamide (OEA) decreased. PEA has prominent anti‐inflammatory properties and
could contribute to suppression of immune function during hibernation. OEA activates the nuclear receptor
PPARα, which plays important roles in lipid metabolism and thermoregulation in hibernation (Carey et al.,
2003a; Ishida, 2009). OEA has been hypothesized to enter the circulation from metabolism of dietary fat and to
function as a satiety factor (Fu et al., 2008). Its reduced concentration in the plasma of hibernating (thus, not
feeding) M. monax is consistent with this notion. The function of 2‐OG has not yet been elucidated.

Figure 5
Endocannabinoid and family members were determined in plasma from Marmota monax during the summer
active period (active) and during a torpor bout in the hibernation period (hibernating). Plasma samples were
purchased from Northeastern Wildlife (Harrison, ID, USA); the samples were from both male and female
animals, and similar proportions of each sex were represented in each time period. Each bar is the mean of
three to five plasma samples; vertical bars represent SEM. Statistical comparisons between summer and
hibernating groups for each lipid were made using unpaired t‐tests; *P < 0.05; **P < 0.01.

Could the pattern of NAEs reflect hibernation‐associated needs for maintaining high PUFA levels in hibernators
discussed above? We speculate that 2‐AG concentrations could be very low because high activity of MGAT
preferentially promotes conversion of 2‐AG to TAG. Additionally, perhaps increased concentrations of PEA, a
saturated FA‐containing NAE, and decreased concentrations of OEA, a mono‐unsaturated FA‐containing NAE,
indicate preferential metabolism of N‐acylPEs containing unsaturated FA. Thus, the pattern of plasma NAEs
could be both the result of, as well as the modulator of, unique hibernation‐associated biological processes. The
roles of the endocannabinoids and their structural cousins in hibernation remain a rich area for future research.

Summary and concluding remarks
Many physiological functions are regulated by circadian rhythms, and data are accumulating that dysregulation
of circadian rhythms or a mismatch between circadian rhythmicity as occurs in modern human society
contribute to human diseases (Takahashi et al., 2008). Bipolar disorder and depression are serious human
psychiatric disorders for which circadian dysregulation is a contributing or causative factor. For example, Clock
mutant mice exhibit a behavioural phenotype that includes many components of mania: hyperactivity in a novel
environment, decreased sleep, risk taking behaviour and reduced anxiety (Roybal et al., 2007). Epidemiological
studies demonstrate that bipolar patients have a 20–40% lifetime likelihood for abusing Cannabis sativa,
compared to 6% in the general US population (Regier et al., 1990). Cannabis use increases the number or
duration of manic episodes, and chronic exposure of humans to Cannabis correlates with an increased incidence
of bipolar disorder (Strakowski and DelBello, 2000). Cannabis consumption in humans is associated with
increased likelihood of developing bipolar disorder; perhaps interactions of THC with circadian rhythms
contribute to this mechanism.
Although the study of hibernation seems distant from human biology, there are several likely sites of
interaction. For example, enhanced understanding of the processes that protect organs during hibernation could
increase organ preservation strategies for transplantation, or during organ failure in diseased humans. On the
other hand, understanding the molecular mechanisms involved in hyperphagia and nutrient storage that occur
in the period preceding hibernation could shed light on the mechanisms of human obesity.
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